# KarMMa-3 (NCT03651128)

> Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03651128
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: bb2121; Daratumumab; Pomalidomide; Dexamethasone; Bortezomib; Ixazomib; Lenalidomide; Carfilzomib; Elotuzumab
- Enrollment: 386
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 134
- X threads: 96
- Podcasts: 68
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=karmma-3-nct03651128

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03651128", "email": "<work email>"}; the inbox owner confirms by the emailed link.